IMMUNE-MEDIATED NECROTIZING MYOPATHY
Clinical trials for IMMUNE-MEDIATED NECROTIZING MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear
Sign up with your email to follow new studies for IMMUNE-MEDIATED NECROTIZING MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC